Dr. Gelbard is recognized for his pioneering work both as a clinician treating Peyronie’s Patients, and as an investigator in contemporary research. His original laboratory work (1982) was the first to identify a potential clinical use for collagenase as a non-surgical treatment of Peyronie’s Disease, and he conducted the first clinical trials with what eventually became Xiaflex®. He authored the first scientific paper advocating the incision of Peyronie’s plaques rather than their excision (1991), a practice that has been widely incorporated into conventional surgical practice around the world. As a result he is one of the most experienced reconstructive surgeons in the urologic community, and has the world’s largest experience with the use of clostridial collagenase histolyticum (Xiaflex) in the treatment of Peyronie’s disease.
Dr. Gelbard is assistant clinical professor of Urology at the UCLA School of Medicine, and practices at Providence Saint Joseph Medical Center in Burbank California. He graduated from Stanford University with a degree in Physical Science and earned his M.D. from the University of California Davis School of Medicine, receiving both Phi Beta Kappa and Alpha Omega Alpha academic honors. After 2 years residency in General Surgery at the UC Davis Medical Center in Sacramento, he completed a 4 year Urology residency at UCLA. During that time he began investigating the modification of scar tissue found in Peyronie’s Disease with clostridial collagenase, a variety of collagen cross-linking inhibitors, and autologous grafting of surgical relaxing incisions.
His original laboratory work (1982) was the first to identify a potential clinical use for collagenase as a non-surgical treatment of Peyronie’s Disease. For this he received the Miley Wesson award from the American Urologic Association in 1984, which encouraged him to conduct as principal investigator the first clinical trials with this agent: an open label pilot study (1985) and the first placebo-controlled double blind study (1993). More recently he has been principal investigator in Xiaflex clinical trials sponsored by Auxilium Pharmaceuticals Inc: a phase I pharmacokinetic study, Phase IIb and III double blind placebo controlled studies, and an open label crossover study.
Dr. Gelbard has remained active both as a clinician in the management of Peyronie’s Patients and as an investigator in contemporary research. He is the author of a number of peer reviewed scientific articles and book chapters.